Insider buying last 90 days
No open-market insider purchases were filed for GILD in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GILD insider filing, plotted on the chart in Gekko.Open GILD in Gekko
NASDAQ: GILD
Gilead Sciences (GILD) Stock Analysis & Forecast
$150.11−0.78 (−0.5%)
Close on Sep 18, 2026. Page updated Sep 19, 9:16 pm ET.
Gekko Brief
AI summaryGilead Sciences closes at $150.11, down 0.5% on the day, with the stock trading above both its 50-day ($139.56) and 200-day ($135.29) moving averages. The GekkoIndex reading sits at 51, placing it in the Neutral zone, while the price stands 3.4% above Gekko Fair Value of $145.18. Over the past year the stock has returned 33.7%, with a three-month return of 21.3%.
This week's news centers on Gilead's HIV prevention franchise, with an agreement with the Pan American Health Organization to expand access to lenacapavir across 14 Latin American and Caribbean countries, alongside an expansion of royalty-free licensing for lenacapavir to 120 countries. Wall Street Zen upgraded the stock to Buy from Hold, with an average price target cited at $158.78. Separately, Nykredit A/S disclosed a new position of over 1.11 million shares valued at approximately $140.59 million, while an executive, Mercier Johanna, sold 3,000 shares in three transactions between $143.69 and $145.29 in the past 90 days.
Gilead's next earnings report is scheduled for 29 October 2026 after close, 39 days away and outside a typical 20-trading-day holding window. At the last report on 3 August 2026, the company posted an EPS beat with a 3.9% reaction, part of a streak of 8 beats in 8 quarters. Seasonality over the next 20 trading days has averaged a 2.2% return across 5 years, positive in 4 of them, worth noting alongside the current gap to Gekko Fair Value.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $150.11200-day averageGekko Fair Value $145.18
Key stats
- Market cap
- $186.4B
- P/E ratio
- —
- Forward P/E
- 15
- EPS, TTM
- −$2.70
- Revenue, TTM
- $30.46B
- Profit margin
- -10.6%
- Dividend yield
- 2.18%
- Beta
- 0.35
- Volume
- 15.59M avg 5.64M
- 1-year return
- +33.7%
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.2%
- 50-day average
- $139.56
- 200-day average
- $135.29
- Next earnings
- Oct 29 after close
- Shares outstanding
- 1.24B
Gilead Sciences swing-trade checklist
Gilead Sciences scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $150.11 is above the 50-day ($139.56) and 200-day ($135.29) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
51, Neutral
Reading 51 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
3.4% above
Price is within 5% of Gekko Fair Value (3.4% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 39 days
Next report Oct 29, 2026, 39 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.2% on average
From this point in the calendar, the next 20 trading days averaged +2.2% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Gilead Sciences stock chart and price history
Gilead Sciences closed at $150.11 on Sep 18, 2026, +33.7% over the past year, inside a 52-week range of $108.46 to $157.29.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.7%
- 3 months
- +21.3%
- 6 months
- +6.4%
- 1 year
- +33.7%
The full GILD chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GILD in Gekko
Follow Gilead Sciences through every session
Put GILD on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GILD in GekkoFree for 7 days. No credit card required.
About Gilead Sciences
Gilead Sciences develops and sells medicines aimed at serious illnesses, with a reach that extends across the United States, Europe, and other markets worldwide. It is widely recognized for its HIV/AIDS treatments, a lineup that includes Biktarvy, Genvoya, Descovy, Odefsey, Truvada, and related therapies. The company also supplies Veklury, an intravenous treatment developed in response to the coronavirus pandemic, alongside medicines for liver disease, cancer, blood disorders, and patients receiving cell therapy.
Beyond its own product lines, Gilead works with outside partners to move new treatments through development. Its collaborators include Arcus Biosciences, Pionyr Immunotherapeutics, Tizona Therapeutics, Tango Therapeutics, Jounce Therapeutics, Galapagos, Janssen Sciences Ireland, Japan Tobacco, Gadeta, Bristol-Myers Squibb, Dragonfly Therapeutics, and Merck. Its portfolio also covers narrower conditions such as pulmonary arterial hypertension, chronic angina, and severe fungal infections, treated respectively with Letairis, Ranexa, and AmBisome.
The company was established in 1987 and runs its headquarters out of Foster City, California. Its shares trade on the NASDAQ under the ticker GILD.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- gilead.com
Gilead Sciences GekkoIndex: the smart money zone
Gilead Sciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51, in the Neutral zone, down 6.8 points over five sessions.
51Neutral
Down 6.8 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 43 | −1.0% | −1.4% | ||
| Accumulation | 165 | +0.7% | +1.4% | ||
| Neutral (current zone) | 409 | +0.7% | +3.2% | ||
| Distribution | 41 | +0.4% | +0.9% | ||
| Selling | 4 | Too few readings yet | |||
Average GILD share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the GILD price, zone by zone.Track GILD in Gekko
Is Gilead Sciences stock overvalued? Gekko Fair Value
Gilead Sciences trades 3.4% above Gekko Fair Value of $145.18, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Gilead Sciences shares are worth, recalculated every trading day.
$145.18
Gekko Fair Value, Sep 19, 2026
3.4% above fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open GILD in Gekko
Gilead Sciences insider and Congress trading
No open-market insider purchases were filed for Gilead Sciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GILD were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GILD, plotted on the chart in Gekko.Open GILD in Gekko
Buybacks
Gilead Sciences has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $355.0M
- As a share of market cap
- 0.19%
- Trailing four quarters
- $1.44B
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold GILD.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Gilead Sciences earnings: next date and track record
Gilead Sciences reports on Oct 29, 2026, after the close (39 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected after the close, 39 days away
- EPS estimate
- $2.15
- Revenue estimate
- $7.77B
8 of 8reports beat the EPS estimate
±4.9%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 3, 2026 AI summary
- What they said
- Gilead reported Q2 2026 base business sales of $7.6 billion, up 10% year-over-year, marking the strongest Q2 growth in 3 years. HIV sales reached $5.7 billion (+12% YoY), with PrEP sales exceeding $1 billion quarterly for the first time. Trodelvy sales surged 26% YoY, Livdelzi more than doubled YoY, and Gilead completed acquisitions of Arcellx and Tubulis to strengthen oncology capabilities.
- Guidance
- Full year 2026 HIV sales growth guidance raised to 9%-10% YoY from prior 8% guidance. Two additional commercial launches expected in H2 2026 in HIV and oncology. BIC/LEN FDA decision expected later in Q3 2026.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | −$6.75 est −$7.07 | $7.80B est $7.40B | +3.9% |
| May 7, 2026 | $2.03 est $1.89 | $6.96B est $6.91B | −3.6% |
| Feb 10, 2026 | $1.86 est $1.81 | $7.93B est $7.69B | +2.7% |
| Oct 30, 2025 | $2.47 est $2.13 | $7.77B est $7.45B | +1.1% |
| Aug 7, 2025 | $2.01 est $1.96 | $7.08B est $6.98B | +8.3% |
| Apr 24, 2025 | $1.81 est $1.77 | $6.67B est $6.81B | −3.0% |
| Feb 11, 2025 | $1.90 est $1.70 | $7.57B est $7.15B | +8.2% |
| Nov 6, 2024 | $2.02 est $1.55 | $7.55B est $7.02B | +8.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Gilead Sciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Gilead Sciences is $158.15, +5.4% from the last close, from 21 firms rating the stock in the last 90 days.
$158.15consensus 12-month target, +5.4% from the last close
Now $150.11Avg $158.15
Low $123High $177
Each firm’s latest rating in the last 90 days: 21 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 10 | HSBC | $175 | +16.6% |
| Sep 7 | Bernstein | $160 | +6.6% |
| Aug 31 | Mizuho Securities | $170 | +13.3% |
| Aug 28 | Scotiabank | $177 | +17.9% |
| Aug 28 | Truist Financial | — | — |
+3.2%average 20-day move after past Neutral readings
+2.2%average move over the next 20 trading days in the last 5 years
±2.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Gilead Sciences seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Gilead Sciences averaged +2.2% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.0% | 0 of 5 |
| Next 10 trading days | −2.7% | 1 of 5 |
| Next 15 trading days | −0.1% | 3 of 5 |
| Next 20 trading days | +2.2% | 4 of 5 |
| Next 30 trading days | +5.1% | 4 of 5 |
For scale, GILD’s typical 20-trading-day move in either direction is about 4.2%.
Gilead Sciences market cap and key statistics
Gilead Sciences’s market cap is $186.4B and revenue of $30.46B over the last twelve months.
Valuation
- Market cap
- $186.4B
- Forward P/E
- 15
- EPS, TTM
- −$2.70
- Gekko Fair Value
- $145.18
Trading
- Volume
- 15.59M
- Avg volume, 20 days
- 5.64M
- 52-week high
- $157.29
- 52-week low
- $108.46
- Shares outstanding
- 1.24B
Financials
- Revenue, TTM
- $30.46B
- Profit margin
- -10.6%
- Return on equity
- -20.7%
- Quarterly earnings growth, YoY
- +54.8%
Risk and income
- Beta
- 0.35
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.2%
- Dividend yield
- 2.18%
Gilead Sciences stock news this week
Coverage of Gilead Sciences this week reads positive: 15 positive, 2 neutral and 2 negative headlines.
- Gilead Sciences (NASDAQ:GILD) Upgraded to Buy at Wall Street ZenMarketBeat, Sep 19
- Gilead Strengthens HIV Growth Platform with Expanded Latin America AccessYahoo Finance, Sep 18
- Nykredit A S Invests $140.59 Million in Gilead Sciences, Inc. $GILDMarketBeat, Sep 18
- Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHFBusiness Wire, Sep 17
- [Press releases] Gilead Sciences provides updates on access to lenacapavir for HIV preventionEuropean AIDS Treatment Group, Sep 17
- GILEAD Sciences (NASDAQ: GILD) Executive Mercier Johanna Disposes of 3,000 Shares in Three Separate SalesKalkine Media, Sep 17
Gilead Sciences peers
Gilead Sciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Accumulation | 31.3% below |
| MRNAModerna | Neutral | 44.3% above |
| NTRANatera | Distribution | 15.3% above |
| IQVIQVIA | Neutral | 10.6% above |
| UTHRUnited Therapeutics | Accumulation | 25.0% below |
| NBIXNeurocrine Biosciences | Buying | 38.9% below |
A peer links to its own page where one exists.
Gilead Sciences stock FAQ
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is $186.4B at the Sep 18, 2026 close of $150.11, with 1.24B shares outstanding.
What is the Gilead Sciences stock forecast?
The consensus analyst 12-month price target for Gilead Sciences is $158.15, +5.4% from the last close. Of the 21 firms that rated the stock in the last 90 days, 17 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Gilead Sciences stock overvalued or undervalued?
On Gekko’s estimate Gilead Sciences is about fair value: the Sep 18, 2026 close of $150.11 is 3.4% above Gekko Fair Value of $145.18. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Gilead Sciences report earnings next?
Gilead Sciences is expected to report on Oct 29, 2026, after the market closes (39 days away). Analysts expect earnings of $2.15 per share on revenue of $7.77B. Gilead Sciences beat the earnings estimate in 8 of its last 8 reports, moving 4.9% on average across the report.
What is Gilead Sciences’s 52-week high and low?
Gilead Sciences’s 52-week high is $157.29 and its 52-week low is $108.46; it closed at $150.11 on Sep 18, 2026, +33.7% over the past year.
Is Gilead Sciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Gilead Sciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.